2023 IASLC North America Conference on Lung Cancer Satellite Symposia
Register Now!
PER's Breast Cancer Symposia in San Antonio
Register Now!
Leukemia Therapy – A Look Into the Future
View More
2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition
Register Now!
Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care
View More
Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers
View More
Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care
View More
FDA Launches Priority Review of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer
December 4th 2023The FDA has granted enfortumab vedotin plus pembrolizumab priority review status for patients with locally advanced or metastatic urothelial cancer following data from the phase 3 EV-302/KEYNOTE-A39 trial.
First-Line Pembrolizumab Shows A Trend Towards Overall Survival in MSI-D/dMMR mCRC
The median overall survival was 77.5 months with frontline pembrolizumab vs 36.7 months with chemotherapy in patients with microsatellite instability–high or mismatch repair–deficient metastatic colorectal cancer.
Pembrolizumab Plus Enzalutamide and ADT Falls Short in mHSPC
Pembrolizumab, in addition to enzalutamide and androgen deprivation therapy, was not associated with better radiographic progression-free survival outcomes in patients with metastatic hormone-sensitive prostate cancer.
Patients With Prostate Cancer Report Better Quality of Life With 18 Months of ADT vs 36 Months
November 23rd 2023Patients with prostate cancer who received 18 months of androgen deprivation therapy were more likely to recover their serum testosterone levels and to recover quicker than those who received 36 months of therapy.